This study checks how safe and effective a medicine called lonigutamab is for people with Thyroid Eye Disease (TED). TED is a condition where the eyes can bulge or feel irritated because of thyroid problems. The study is in Phase 1/2, which means it's early in testing but involves multiple centers and doses.

• The study is for adults aged 18-75 with specific eye symptoms.
• Participants must not have certain health issues like hearing problems or diabetes.
• Participants should not have used certain medicines or treatments for TED recently.

It's important to know that you have to agree to use strong birth control if you join. If you've had certain treatments or surgeries for TED before, you might not be able to join. The study involves several visits to the clinic and might include some risks, like any clinical trial. Always talk with your doctor to understand if this study is a good fit for you.